Treatment of refractory and relapsed acute myelogenous leukemia

Expert Review of Anticancer Therapy

Volumn 2, Issue 3, 2002, Pages 287-295

  Stanisic, Slobodan ^a   Kalaycio, Matt ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Allogeneic bone marrow transplant; Gemtuzumab ozogamicin; Multidrug resistance; Refractory AML; Relapsed AML

Indexed keywords

ANTHRACYCLINE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALICHEAMICIN DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DIAZIQUONE; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GLYCOPROTEIN P; GRANULOCYTE COLONY STIMULATING FACTOR; HUM 195; LEUKOCYTE ANTIGEN; MITOXANTRONE; MONOCLONAL ANTIBODY; NUCLEOSIDE ANALOG; PROTEIN FARNESYLTRANSFERASE INHIBITOR; QUININE; SIALIC ACID DERIVATIVE; TAMOXIFEN; TIPIFARNIB; TOPOTECAN; TROXACITABINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DONOR; DRUG EFFICACY; FEVER; GRAFT VERSUS LEUKEMIA EFFECT; HLA MATCHING; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; LEUKEMIA REMISSION; LONG TERM CARE; MAJOR CLINICAL STUDY; NEUTROPENIA; REFRACTORY ANEMIA; REVIEW; SALVAGE THERAPY; TREATMENT FAILURE; WHOLE BODY RADIATION;

EID: 0036084351     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.2.3.287     Document Type: Review

References (61)

1. Intensifying induction therapy in acute myeloid leukemia: Has a new standard of care emerged?
2. Response to salvage therapy and survival after relapse in acute myelogenous leukemia
3. Report of the National Cancer Institute-sponsored workshop on the definitions of diagnosis and response in acute myeloid leukemia
4. Design and analysis of trials of salvage therapy in acute myelogenous leukemia
5. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation and allogeneic bone marrow transplantation
6. Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia
7. Bone marrow transplantation for primary refractory acute leukaemia
8. Bone-marrow ablation and allogeneic marrow transplantation in acute leukemia
9. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia
10. Allogeneic marrow transplantation for acute nonlymhoblastic leukemia after first relapse
11. The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation
12. Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors
13. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: The effect of leukemia burden, donor HLA-matching and marrow cell dose
14. Chemotherapy based nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation
15. Temporal relationships between the major complications of bone marrow transplantation for leukaemia
16. Leukemia: Management of relapse after allogeneic bone marrow transplantation
17. Second allogeneic bone marrow transplantation in acute leukemia: Results of a survey by the European Co-operative Group for Blood and Marrow Transplantation
18. Relapse after allogeneic bone marrow transplantation for acute leukaemia: A survey by the E.B.M.T. of 117 cases
19. The role of repeat transplantation of haemopoietic stem cells and adoptive immunotherapy in treatment of leukaemia relapsing following allogeneic transplantation
20. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions
21. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens
22. Second HLA-identical sibling transplants for leukemia recurrence
23. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
24. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties
25. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions
26. Autologous stem cell transplantation in acute myelocytic leukemia
27. Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission
28. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia
29. High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy
30. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia - An active and well-tolerated regimen
31. Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON)
32. Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: A CALGB Phase I study
33. High-dose cytosine arabinoside and mitoxantrone: A highly effective regimen in refractory acute myeloid leukemia
34. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: Long-term follow-up of the etoposide, mitoxantrone and cytarabine-86 trial
35. Fludarabine, cytarabine and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia
36. A multicentre, open, non-comparative Phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo with excess of blasts in transformation
37. Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia
38. Effect of complete remission on survival in patients with acute myelogenous leukemia receiving first salvage therapy
39. Introduction: Emerging therapies for hematologic malignancies: Antibodies, antisense and cytokine approaches
40. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A Phase I study of an antiCD33 calicheamicin immunoconjugate
41. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
42. Update of prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin followed by hematopoietic stem cell transplantation
43. Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia
44. Flow cytometry determination of the multi-drug resistant phenotype in acute leukemia
45. Multi-drug resistance and its pharmacologic modulation in acute leukemia
46. Benefit of cyclosporin modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study
47. Mitoxantrone, etoposide and cytarabine plus cyclosporin for patients with relapsed or refractory acute myeloid leukemia: An Eastern Co-operative Oncology Group pilot study
48. Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporin, in refractory/relapsed acute myeloid leukaemia (AML): Results of the UK Medical Research Council AML-R trial
49. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia
50. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multi-drug resistance modulator PSC 833 (Valspodar)
51. Treatment of refractory/relapsed AML with PSC-833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs. MEC: Randomized Phase III trial. (E2995)
52. High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia
53. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A Phase I clinical-laboratory correlative trial
54. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia
55. Evidence of increased angiogenesis in patients with acute myeloid leukemia
56. Efficacy and safety of thalidomide in patients with acute myeloid leukemia
57. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia
58. Decitabine studies in chronic and acute myelogenous leukemia
59. Evaluation of humanized antiCD33 monoclonal antibody (HuM195) as a single agent in the treatment of relapsed or refractory acute myeloid leukemia
60. What is the curative potential of refractory leukemia with related and unrelated allogeneic transplants?